Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pathogenic implications of iron accumulation in multiple sclerosis.
Interferon-beta(1b) treatment in neuromyelitis optica.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Nanoparticle transport across the blood brain barrier.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
The challenge of comorbidity in clinical trials for multiple sclerosis.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
A gender gap in autoimmunity.
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

Pages